Efficacy of Short-Course Antibiotic Regimens for Community-Acquired Pneumonia: A Meta-analysis

American Journal of Medicine

Volumn 120, Issue 9, 2007, Pages 783-790

  Li, Jonathan Z ^a   Winston, Lisa G ^a,b   Moore, Dan H ^a   Bent, Stephen ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibiotics; Community acquired pneumonia; Pneumonia; Short course

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFACLOR; CEFTRIAXONE; CEFUROXIME; CLARITHROMYCIN; ERYTHROMYCIN; GEMIFLOXACIN; JOSAMYCIN; KETOLIDE; LEVOFLOXACIN; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN; TELITHROMYCIN;

ADULT; ARTICLE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; EMBASE; HUMAN; MAJOR CLINICAL STUDY; MEDLINE; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; PNEUMONIA; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 34548172901     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2007.04.023     Document Type: Article

References (59)

1. Bartlett J.G., Dowell S.F., Mandell L.A., et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 31 2 (2000) 347-382
2. Mandell L.A. Epidemiology and etiology of community-acquired pneumonia. Infect Dis Clin North Am 18 4 (2004) 761-776 Dec, vii
3. File Jr. T.M., Garau J., Blasi F., et al. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. Chest 125 5 (2004) 1888-1901
4. Segreti J., House H.R., and Siegel R.E. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting. Am J Med 118 7 Suppl (2005) 21S-28S
5. File Jr. T.M. Community-acquired pneumonia. Lancet 362 9400 (2003) 1991-2001
6. Mills G.D., Oehley M.R., and Arrol B. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ 330 7489 (2005) 456
7. Niederman M.S., Mandell L.A., Anzueto A., et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 163 7 (2001) 1730-1754
8. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44 Suppl 2 (2007) S27-S72
9. Mandell L.A., Bartlett J.G., Dowell S.F., et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 37 11 (2003) 1405-1433
10. Mandell L.A., Marrie T.J., Grossman R.F., et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 31 2 (2000) 383-421
11. Halm E.A., and Teirstein A.S. Clinical practice. Management of community-acquired pneumonia. N Engl J Med 347 25 (2002) 2039-2045
12. Bjerre L.M., Verheij T.J., and Kochen M.M. Antibiotics for community acquired pneumonia in adult outpatients. Cochrane Database Syst Rev 2 (2004) CD002109
13. Shefet D., Robenshtok E., Paul M., and Leibovici L. Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials. Arch Intern Med 165 17 (2005) 1992-2000
14. BTS guidelines for the management of community acquired pneumonia in adults. Thorax 56 Suppl 4 (2001) IV1-IV64
15. Contopoulos-Ioannidis D.G., Ioannidis J.P., Chew P., and Lau J. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections. J Antimicrob Chemother 48 5 (2001) 691-703
16. File Jr. T.M. Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia. Clin Infect Dis 39 Suppl 3 (2004) S159-S164
17. Hopkins S., and Williams D. Five-day azithromycin in the treatment of patients with community-acquired pneumonia. Curr Ther Res Clin Exp 56 9 (1995) 915-925
18. Socan M. Treatment of atypical pneumonia with azithromycin: comparison of a 5-day and a 3-day course. J Chemother 10 1 (1998) 64-68
19. Mandell L.A., and File Jr. T.M. Short-course treatment of community-acquired pneumonia. Clin Infect Dis 37 6 (2003) 761-763
20. Kolditz M., Halank M., and Hoffken G. Short-course antimicrobial therapy for community-acquired pneumonia. Treat Respir Med 4 4 (2005) 231-239
21. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 17 1 (1996) 1-12
22. Fine M.J., Auble T.E., Yealy D.M., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336 4 (1997) 243-250
23. Bohte R., Van't Wout J.W., Lobatto S., et al. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 14 3 (1995) 182-187
24. Brion J.P., Sedallian A., Le Noc P., et al. Azithromycin versus josamycin: treatment of 89 acute pneumonia cases. Pathol Biol (Paris) 38 5 Pt 2 (1990) 521-525
25. Kinasewitz G., and Wood R.G. Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia. Eur J Clin Microbiol Infect Dis 10 10 (1991) 872-877
26. Kobayashi H., Sakayori S., Koike T., et al. Clarithromycin-controlled randomized double-blind studies of azithromycin for treatment of pneumonia. Jpn J Chemother 43 8 (1995) 757-774
27. O'Doherty B., and Muller O. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 17 12 (1998) 828-833
28. Rahav G., Fidel J., Gibor Y., and Shapiro M. Azithromycin versus comparative therapy for the treatment of community acquired pneumonia. Int J Antimicrob Agents 24 2 (2004) 181-184
29. Rizzato G., Montemurro L., Fraioli P., et al. Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia. Eur Respir J 8 3 (1995) 398-402
30. Schonwald S., Barsic B., Klinar I., and Gunjaca M. Three-day azithromycin compared with ten-day roxithromycin treatment of atypical pneumonia. Scand J Infect Dis 26 6 (1994) 706-710
31. Schonwald S., Gunjaca M., Kolacny-Babic L., et al. Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias. J Antimicrob Chemother 25 Suppl A (1990) 123-126
32. Sopena N., Martinez-Vazquez C., Rodriguez-Suarez J.R., et al. Comparative study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of community-acquired pneumonia in adults. J Chemother 16 1 (2004) 102-103
33. Dunbar L.M., Wunderink R.G., Habib M.P., et al. High-dose, short-course levofloxacin for community-acquired pneumonia: A new treatment paradigm. Clin Infect Dis 37 6 (2003) 752-760
34. Leophonte P., File T., and Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir Med 98 8 (2004) 708-720
35. Leophonte P., Choutet P., Gaillat J., et al. Efficacy of a ten day course of ceftriaxone compared to a shortened five day course in the treatment of community-acquired pneumonia in hospitalized adults with risk factors. Med Mal Infect 32 7 (2002) 369-381
36. Siegel R.E., Alicea M., Lee A., and Blaiklock R. Comparison of 7 versus 10 days of antibiotic therapy for hospitalized patients with uncomplicated community-acquired pneumonia: a prospective, randomized, double-blind study. Am J Ther 6 4 (1999) 217-222
37. Tellier G., Niederman M.S., Nusrat R., et al. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother 54 2 (2004) 515-523
38. File Jr. T.M., and Niederman M.S. Antimicrobial therapy of community-acquired pneumonia. Infect Dis Clin North Am 18 4 (2004) 993-1016
39. Restrepo M.I., and Anzueto A. Antimicrobial treatment of community-acquired pneumonia. Clin Chest Med 26 1 (2005) 65-73
40. Pakistan Multicentre Amoxycillin Short Course Therapy (MASCOT) pneumonia study group. Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: a multicentre double-blind trial. Lancet 360 9336 (2002) 835-841
41. Agarwal G., Awasthi S., Kabra S.K., et al. Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: a multicentre randomised controlled trial. BMJ 328 7443 (2004) 791
42. Awunor-Renner C. Length of antibiotic therapy in in-patients with primary pneumonias. Ann Trop Med Parasitol 73 3 (1979) 235-240
43. Chastre J., Wolff M., Fagon J.Y., et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 290 19 (2003) 2588-2598
44. Montravers P., Fagon J.Y., Chastre J., et al. Follow-up protected specimen brushes to assess treatment in nosocomial pneumonia. Am Rev Respir Dis 147 1 (1993) 38-44
45. Foulds G., Shepard R.M., and Johnson R.B. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 25 Suppl A (1990) 73-82
46. el Moussaoui R., de Borgie C.A., van den Broek P., et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ 332 7554 (2006) 1355
47. Richter S.S., Heilmann K.P., Beekmann S.E., et al. The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations. Clin Infect Dis 40 2 (2005) 225-235
48. Karchmer A.W. Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US-an update. Clin Infect Dis 39 Suppl 3 (2004) S142-S150
49. Doern G.V. Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States. Clin Infect Dis 33 Suppl 3 (2001) S187-S192
50. Schrag S.J., Pena C., Fernandez J., et al. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. JAMA 286 1 (2001) 49-56
51. Kardas P. Patient compliance with antibiotic treatment for respiratory tract infections. J Antimicrob Chemother 49 6 (2002) 897-903
52. Reyes H., Guiscafre H., Munoz O., et al. Antibiotic noncompliance and waste in upper respiratory infections and acute diarrhea. J Clin Epidemiol 50 11 (1997) 1297-1304
53. Cunha B.A. Antimicrobial therapy of multidrug-resistant Streptococcus pneumoniae, vancomycin-resistant enterococci, and methicillin-resistant Staphylococcus aureus. Med Clin North Am 90 6 (2006) 1165-1182
54. Karlowsky J.A., Thornsberry C., Jones M.E., et al. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002). Clin Infect Dis 36 8 (2003) 963-970
55. Davidson R., Cavalcanti R., Brunton J.L., et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 346 10 (2002) 747-750
56. Whitney C.G., Farley M.M., Hadler J., et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 343 26 I (2000) 1917-1924
57. Powis J., McGeer A., Green K., et al. In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002. Antimicrob Agents Chemother 48 9 (2004) 3305-3311
58. Clay K.D., Hanson J.S., Pope S.D., et al. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med 144 6 (2006) 415-420
59. Ross D. The FDA and the case of Ketek. N Engl J Med 356 16 (2007) 1601-1604